Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.50 |
| ▸ | ABL1 | P00519 | 8/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22625527 | 0.90 | RAF1 (0.53) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL23745199 | 0.84 | RAF1 (0.55) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL22625505 | 0.84 | RAF1 (0.55) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL22612716 | 0.80 | RAF1 (0.61) | RAF1ABL1KDRBRAFLCK | |
| SCHEMBL22625576 | 0.78 | RAF1 (0.60) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL22612960 | 0.76 | RAF1 (0.55) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL30439904 | 0.76 | RAF1 (0.55) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL22612847 | 0.76 | RAF1 (0.55) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL22612912 | 0.76 | RAF1 (0.53) | RAF1ABL1KDRBRAFKRAS | |
| SCHEMBL29427309 | 0.76 | RAF1 (0.53) | RAF1ABL1KDRBRAFKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | RAF1 2/4885ABL1 8/4885KDR 113/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | RAF1 2/4885ABL1 8/4885KDR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.